49.51
price up icon1.43%   0.70
after-market Dopo l'orario di chiusura: 49.37 -0.14 -0.28%
loading
Precedente Chiudi:
$48.81
Aprire:
$47.1
Volume 24 ore:
1.72M
Relative Volume:
0.91
Capitalizzazione di mercato:
$4.75B
Reddito:
$3.51M
Utile/perdita netta:
$-581.60M
Rapporto P/E:
-7.60
EPS:
-6.5145
Flusso di cassa netto:
$-345.93M
1 W Prestazione:
+4.12%
1M Prestazione:
-18.53%
6M Prestazione:
-32.01%
1 anno Prestazione:
+44.81%
Intervallo 1D:
Value
$47.10
$49.95
Intervallo di 1 settimana:
Value
$44.12
$49.95
Portata 52W:
Value
$30.04
$78.48

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name
Nome
Crispr Therapeutics Ag
Name
Telefono
(617) 315-4600
Name
Indirizzo
BAARERSTRASSE 14, ZUG
Name
Dipendente
393
Name
Cinguettio
@crisprtx
Name
Prossima data di guadagno
2025-10-31
Name
Ultimi documenti SEC
Name
CRSP's Discussions on Twitter

Compare CRSP vs VRTX, REGN, ARGX, ALNY, INSM

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
CRSP icon
CRSP
Crispr Therapeutics Ag
49.51 4.75B 3.51M -581.60M -345.93M -6.5145
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
438.71 111.45B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
761.85 80.54B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
746.42 46.32B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
318.85 42.29B 3.71B 313.75M 465.38M 2.2571
INSM icon
INSM
Insmed Inc
162.43 35.01B 606.42M -1.28B -997.58M -6.403

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-09-18 Iniziato JP Morgan Overweight
2025-02-14 Aggiornamento Evercore ISI In-line → Outperform
2025-02-12 Aggiornamento TD Cowen Sell → Hold
2025-02-03 Iniziato H.C. Wainwright Buy
2024-08-06 Reiterato Needham Buy
2024-08-02 Iniziato Rodman & Renshaw Buy
2024-06-28 Ripresa Guggenheim Neutral
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-12-11 Downgrade TD Cowen Market Perform → Underperform
2023-10-17 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-09-27 Iniziato Mizuho Buy
2023-08-17 Aggiornamento Citigroup Neutral → Buy
2023-05-30 Iniziato William Blair Outperform
2023-04-13 Iniziato Cantor Fitzgerald Overweight
2023-03-21 Iniziato Bernstein Mkt Perform
2023-03-17 Iniziato Bryan Garnier Buy
2023-03-07 Iniziato Robert W. Baird Neutral
2022-10-11 Iniziato Morgan Stanley Underweight
2022-08-09 Downgrade Barclays Overweight → Equal Weight
2022-06-23 Downgrade Evercore ISI Outperform → In-line
2022-06-17 Iniziato BMO Capital Markets Outperform
2022-04-28 Iniziato Credit Suisse Neutral
2021-12-07 Iniziato Cowen Market Perform
2021-10-19 Iniziato SVB Leerink Outperform
2021-06-14 Aggiornamento Citigroup Sell → Neutral
2021-04-21 Aggiornamento Jefferies Hold → Buy
2021-03-04 Iniziato JMP Securities Mkt Outperform
2020-12-10 Reiterato Chardan Capital Markets Buy
2020-12-10 Downgrade Jefferies Buy → Hold
2020-12-10 Reiterato Needham Buy
2020-12-07 Downgrade Wells Fargo Overweight → Equal Weight
2020-10-23 Iniziato RBC Capital Mkts Sector Perform
2020-10-05 Iniziato BofA Securities Buy
2020-07-28 Reiterato Needham Buy
2020-07-14 Iniziato SunTrust Buy
2020-06-15 Reiterato Canaccord Genuity Buy
2020-03-05 Iniziato Stifel Hold
2020-02-03 Downgrade Evercore ISI Outperform → In-line
2019-11-19 Aggiornamento William Blair Mkt Perform → Outperform
2019-11-12 Aggiornamento Oppenheimer Perform → Outperform
2019-08-01 Iniziato Jefferies Buy
2019-07-26 Iniziato Canaccord Genuity Buy
2019-06-10 Iniziato ROTH Capital Buy
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-14 Iniziato William Blair Mkt Perform
2019-01-28 Downgrade Goldman Buy → Neutral
2019-01-22 Downgrade Citigroup Neutral → Sell
Mostra tutto

Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie

pulisher
05:37 AM

CRISPR Therapeutics AG (CRSP) latest stock news and headlines - Yahoo Finance Australia

05:37 AM
pulisher
12:05 PM

CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada

12:05 PM
pulisher
Apr 04, 2026

CRISPR Therapeutics AG (CRSP) stock price, news, quote and history - Yahoo Finance UK

Apr 04, 2026
pulisher
Apr 04, 2026

Assessing CRISPR Therapeutics (CRSP) Valuation As Casgevy Revenue And Cash Position Support Its Growth Transition - sahmcapital.com

Apr 04, 2026
pulisher
Apr 03, 2026

CRISPR Therapeutics Hits Day Low of $50.66 Amid Price Pressure - Markets Mojo

Apr 03, 2026
pulisher
Apr 03, 2026

Did CRISPR’s Cash Raise, Casgevy Launch and Insider Buying Just Shift CRISPR Therapeutics' (CRSP) Investment Narrative? - Sahm

Apr 03, 2026
pulisher
Apr 02, 2026

CRISPR Therapeutics AG (CRSP) rises higher than market: Key facts - MSN

Apr 02, 2026
pulisher
Apr 02, 2026

CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts - Yahoo Finance

Apr 02, 2026
pulisher
Apr 02, 2026

CRISPR Therapeutics (NASDAQ: CRSP) asks shareholders to approve pay, capital and equity plan - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

CRISPR Therapeutics AG (0VRQ.L) stock price, news, quote and history - Yahoo Finance UK

Apr 02, 2026
pulisher
Apr 02, 2026

CRISPR Therapeutics AG (CRSP) exceeds market returns: Some facts to consider - MSN

Apr 02, 2026
pulisher
Apr 01, 2026

CRISPR Therapeutics AG (CRSP) Outperforms the Market: Key Points to Note - Bitget

Apr 01, 2026
pulisher
Apr 01, 2026

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance

Apr 01, 2026
pulisher
Apr 01, 2026

Earnings Beat: Is CRISPR Therapeutics AG backed by strong institutional buying2026 Institutional Moves & Low Risk Entry Point Tips - baoquankhu1.vn

Apr 01, 2026
pulisher
Apr 01, 2026

A Turning Point For Crispr Therapeutics As Commercial Growth Accelerates (NASDAQ:CRSP) - seekingalpha.com

Apr 01, 2026
pulisher
Apr 01, 2026

Bond Watch: Is CRISPR Therapeutics AG backed by strong institutional buying2026 Chart Watch & Weekly High Return Stock Opportunities - baoquankhu1.vn

Apr 01, 2026
pulisher
Mar 31, 2026

Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail

Mar 31, 2026
pulisher
Mar 31, 2026

I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds Expectations (CRSP) - seekingalpha.com

Mar 31, 2026
pulisher
Mar 31, 2026

CRISPR Therapeutics: The Fundamental Standard-Bearer in a Fractured Genomic Sector - Barchart

Mar 31, 2026
pulisher
Mar 31, 2026

CRISPR (CRSP) Rated Overweight on Gene Editing Growth - Insider Monkey

Mar 31, 2026
pulisher
Mar 31, 2026

CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo

Mar 31, 2026
pulisher
Mar 30, 2026

CRISPR Therapeutics shares drop after announcing convertible notes sale - MSN

Mar 30, 2026
pulisher
Mar 29, 2026

Return on equity % of CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh – SET:CRSP03 - TradingView

Mar 29, 2026
pulisher
Mar 29, 2026

(CRSP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Mar 29, 2026
pulisher
Mar 28, 2026

Is CRISPR Therapeutics (CRSP) Attractive After Recent Share Price Pullback? - Yahoo Finance

Mar 28, 2026
pulisher
Mar 28, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 28, 2026
pulisher
Mar 28, 2026

Why CRISPR Therapeutics AG (CRSP) outpaced the stock market today - MSN

Mar 28, 2026
pulisher
Mar 27, 2026

Trend Report: What is the long term forecast for CRISPR Therapeutics AG stockTrade Entry Report & Accurate Intraday Trading Signals - baoquankhu1.vn

Mar 27, 2026
pulisher
Mar 26, 2026

CRISPR Therapeutics stock faces uncertainty ahead of key earnings amid biotech sector volatility - AD HOC NEWS

Mar 26, 2026
pulisher
Mar 26, 2026

Truist Financial Upgrades CRISPR Therapeutics (NASDAQ:CRSP) to "Strong-Buy" - marketbeat.com

Mar 26, 2026
pulisher
Mar 25, 2026

CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it - msn.com

Mar 25, 2026
pulisher
Mar 25, 2026

Why CRISPR Therapeutics AG (CRSP) Performed Better Than the Market Today - Bitget

Mar 25, 2026
pulisher
Mar 25, 2026

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today - Yahoo! Finance Canada

Mar 25, 2026
pulisher
Mar 25, 2026

CRISPR Therapeutics stock dips on $350M convertible debt offering - MSN

Mar 25, 2026
pulisher
Mar 25, 2026

CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 3,182 Shares - MarketBeat

Mar 25, 2026
pulisher
Mar 25, 2026

CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,020 Shares - MarketBeat

Mar 25, 2026
pulisher
Mar 24, 2026

Crispr Therapeutics Insider Sold Shares Worth $468,736, According to a Recent SEC Filing - marketscreener.com

Mar 24, 2026
pulisher
Mar 24, 2026

CRISPR (CRSP) GC granted options, RSUs; sells shares for taxes - stocktitan.net

Mar 24, 2026
pulisher
Mar 24, 2026

CRISPR Therapeutics (CRSP) CEO gets major equity awards, sells shares for taxes - Stock Titan

Mar 24, 2026
pulisher
Mar 24, 2026

[Form 4] CRISPR Therapeutics AG Insider Trading Activity - Stock Titan

Mar 24, 2026
pulisher
Mar 24, 2026

CRISPR Therapeutics (NASDAQ: CRSP) grants CMO stock options and RSUs - Stock Titan

Mar 24, 2026
pulisher
Mar 24, 2026

CRISPR Therapeutics Hits Day Low of $45.88 Amid Price Pressure - Markets Mojo

Mar 24, 2026

Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$99.12
price up icon 0.49%
$28.33
price up icon 1.76%
$48.57
price up icon 0.16%
$91.18
price up icon 1.97%
ONC ONC
$310.79
price up icon 0.76%
$162.43
price down icon 1.47%
Capitalizzazione:     |  Volume (24 ore):